KCM
ICPT

Kingdon Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Kingdon Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-6,000
Closed -$1.42M – 178
2014
Q3 		$1.42M Buy
+6,000
New +$1.53M 0.06% 147

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Kingdon Capital Management's ICPT Position: Q4 2014 in Review

Kingdon Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2014, closing a stake of 6,000 shares — an estimated $1.42M sold.

Kingdon Capital Management first reported a position in ICPT in Q3 2014 and held it in 1 quarter. The position peaked at $1.42M in Q3 2014. 169 funds tracked by Wall St. Rank hold ICPT as of Q4 2014.

  • Kingdon Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2014 after selling out during the quarter.
  • Kingdon Capital Management sold 6,000 Intercept Pharmaceuticals, Inc. shares in Q4 2014, an estimated $1.42M.
  • Kingdon Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2014 and held it in 1 quarter.
  • Kingdon Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $1.42M in Q3 2014.
  • 169 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2014.

Based on Kingdon Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.